Plague vaccine granted Orphan Drug designation from FDA

CSRA Inc. today announced that a plague vaccine being developed by its subsidiary, DynPort Vaccine Company LLC (DVC), was granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA). DVC is developing the recombinant rF1V plague vaccine on behalf of the U.S. Department of Defense (DoD). The vaccine will be used for pre-exposure prophylaxis ["]

The post Plague vaccine granted Orphan Drug designation from FDA appeared first on Outbreak News Today.